Natural Health Trends (NHTC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Feb, 2026Executive summary
Q4 2025 revenue rose 3% sequentially to $9.7 million but declined 10% year-over-year; full-year 2025 revenue was $39.8 million, down 7% from 2024.
Full year showed signs of stabilization, with increased reorder rates and 10% growth in curated product bundle sales.
Growth in Taiwan and Peru in Q4, with strong annual increases in Japan and Colombia.
Restructuring initiatives aimed at $1.5 million annualized savings are nearly complete, with a significant shift in product sourcing to East Asia.
A quarterly cash dividend of $0.10 per share was declared, payable in February 2026.
Financial highlights
Gross profit margin was 72.9% in Q4, down from 74.2% last year due to inventory write-offs from discontinued and relocated products.
Commissions expenses were 40.3% of net sales, down from 41.9% a year ago.
SG&A expenses were $3.8 million, with $208,000 in restructuring charges.
Operating loss was $635,000 in Q4; excluding restructuring, operating loss would have been $352,000.
Net loss for Q4 was $588,000 ($0.05 per diluted share), compared to net income of $176,000 ($0.02 per share) last year.
Full-year net loss was $882,000 ($0.08 per diluted share) versus net income of $572,000 in 2024.
Net cash used in operations was $959,000 in Q4 and $6 million for the year; cash, equivalents, and marketable securities totaled $28.9 million at year-end.
$9.2 million in dividends paid during 2025.
Outlook and guidance
Restructuring initiatives are nearly complete, with $1.5 million in annualized cost savings expected in 2026.
25th anniversary year in 2026 expected to drive renewed momentum through special events and product launches.
Business positioned for improved profitability and performance in 2026.
Latest events from Natural Health Trends
- Shareholders will vote on director elections, a new equity plan, and auditor ratification.NHTC
Proxy filing24 Mar 2026 - Director elections, equity plan, and auditor ratification up for vote at May 2026 meeting.NHTC
Proxy filing24 Mar 2026 - Annual meeting to elect directors, approve equity plan, and ratify auditor, with focus on governance.NHTC
Proxy filing24 Mar 2026 - Flat Q2 sales, improved profit, and Hong Kong's first sales growth since Q1 2023.NHTC
Q2 20242 Feb 2026 - Q3 2024 sales up 1% to $10.7M, net income $35K, and $0.20 dividend declared.NHTC
Q3 202417 Jan 2026 - Q4 2024 revenue flat, Greater China up 7%, net income $176K, $9.2M dividends paid.NHTC
Q4 202424 Dec 2025 - Revenue down 2% year-over-year, orders up 9%, $0.20 dividend declared, trade risks persist.NHTC
Q1 202523 Dec 2025 - Annual meeting to elect five directors and ratify CBIZ CPAs P.C. as auditor for 2025.NHTC
Proxy Filing2 Dec 2025 - Vote on director elections and auditor ratification at the May 2025 annual meeting.NHTC
Proxy Filing2 Dec 2025